Howard A. "Skip" Burris, III, MD, FACP, FASCO
Immunotherapy, PARP inhibitors, and antibody-drug conjugates (ADCs) have shown clinical benefit in patients with metastatic triple-negative breast cancer (TNBC). The use of these treatments is guided in part by the predictive value of PD-L1 expression and BRCA
mutations, explained Howard A. "Skip" Burris, III, MD, FACP, FASCO.
... to read the full story